The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers.

Grail is partnering with Samsung to move into Asia. The innovative cancer test maker just got major new sources of funding. Well, Grail makes a multicancer early-detection test called Galleri that ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California (Reuters) -Shares of Grail fell ...

CHICAGO, June 24 (Reuters) - U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina (ILMN.O ...

GRAL shares collapsed 50.55% on February 20, 2026, erasing $51.32 per share in value after the Company disclosed its NHS-Galleri trial failed to achieve its primary endpoint. Investors have until ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 4, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of ...